2018 American Transplant Congress
Four Eyes Are Better Than Two: Improving Laboratory Report Quality Control
1Quality Assurance, LABS, Inc., Centennial, CO; 2Infectious Disease, LABS, Inc., Philadelphia, PA.
Background: Our STAT donor-screening lab implemented a new LIMS that is used to manage patient orders, testing and reporting. We intentionally customized the LIMS to…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…2018 American Transplant Congress
Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan
Background and purpose: After the approval of everolimus (EVR) in 2011 in Japan to prevent organ rejection in kidney transplant (KTx) patients, no data on…2018 American Transplant Congress
Excellent Outcomes for HCV-Viremic Recipients of Simultaneous Liver-Kidney Transplant in the Direct Anti-Viral Era
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
Before the era of direct anti-viral agents (DAAs), outcomes for HCV-viremic recipients of simultaneous liver kidney transplant (SLKT) were inferior to HCV-negative recipients. PURPOSE: To…2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…2018 American Transplant Congress
Risk Factors for Postoperative Bleeding after Lung Transplantation
Bleeding complications after lung transplantation (LuTX) are associated with increased morbidity. Risk factors for postoperative bleeding complications after LuTX have not yet been reported. In…2018 American Transplant Congress
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
University of North Carolina, Chapel Hill.
Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…2018 American Transplant Congress
Water-Jet Dissection for Donor Hepatectomy during Living Donor Liver Transplantation
Background The most important issue in living donor liver transplantation (LDLT) is donor safety. Although donor hepatectomy has evolved technically over the years, it is…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Laparoscopic Donor Nephrectomy Safety: Experience of 500 Cases in Hispanic Population at a Single Institution
Transplantation Surgery, Colombiana de Trasplantes, Bogota, Colombia.
Background: Laparoscopic live donor nephrectomy (LDN) has become the best option in living donation because its safety and low rate of complications. This report aims…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 19
- Next Page »